Organon & Co.
Tracked across 9 events · 93 articles · First seen May 23, 2025 · Last active May 25, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Organon & Co. is the primary defendant in the class action lawsuit, accused of making misleading statements regarding its capital allocation priorities and dividend payout, which led to a significant stock price drop.
May 23, 2025 · 7 articles
Business
Impact: Organon & Co. is facing a class action lawsuit for allegedly making false and misleading statements regarding its capital allocation and debt reduction strategy, which led to a significant drop in its stock price.
May 29, 2025 · 6 articles
Business
Impact: Organon & Co. is facing a federal securities class action lawsuit for allegedly making false and misleading statements regarding its capital allocation strategy and dividend priorities, which led to a significant stock price decline.
May 23, 2025 · 6 articles
Business
Impact: Organon & Co. is being sued for securities fraud after allegedly misleading investors about its capital allocation priorities, leading to a significant dividend cut and a 27% stock price decline. The company's actions have negatively impacted its stock price and reputation.
May 31, 2025 · 21 articles
Business
Impact: Organon & Co. is facing a class action lawsuit for allegedly misleading investors about its capital allocation strategy, particularly regarding dividend payments and debt reduction following its acquisition of Dermavant. This led to a significant drop in its stock price.
May 30, 2025 · 6 articles
Business
Impact: Organon & Co. is facing a class action lawsuit for allegedly making false and misleading statements regarding its capital allocation and debt reduction strategy, which led to a 70% decrease in its quarterly dividend and investor damages.
May 29, 2025 · 6 articles
Roivant Sciences
acquirer
↔
Organon & Co.
Organon & Co. acquired Roivant Sciences for $1.2 billion in October 2024, a tran
Roivant Sciences
target
↔
Organon & Co.
Roivant Sciences was acquired by Organon & Co. for $1.2 billion in October 2024.
NEWSDESK
Track Organon & Co. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard